Researchers at Hiroshima University and Gifu Kyoritsu University identified Hepatitis B RNA serum levels as a biomarker that more accurately ...
Chronic hepatitis B is a viral disease that affects the liver and greatly increases the risks of liver cirrhosis and ...
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Read more about how a dive in HBV rates in infants in the USA has undone years of steady increase in vaccination uptake.
Newborn hepatitis B virus vaccination rates in the U.S. decreased by over 10 percentage points in the last 2 years after ...
Dr. Chas Hannum of Tufts Medical Center addresses the sharp drop in newborns receiving the hepatitis B vaccine.
Background People living with HIV (PWH) are at increased risk of cardiovascular disease; however, evidence from Asian ...
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approxima ...
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of ...
Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively ...
Joint AASLD/IDSA practice recommendations reflect new data on prevention, treatment, and surveillance of chronic hepatitis B, ...
The Supreme Court sought detailed information on the costs and availability of conducting Nucleic Acid Amplification Testing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results